BioMarin Pharmaceutical Stock Forecast

Stock Price Forecast

According to 27 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $91.62. The average 1-year stock price forecast is 52.04% higher than the current stock price, while the lowest is $60 (-0.43%) and the highest is $124 (+105.77%).

Price Target: $91.62 (+52.04%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$60	$91.62	$90	$124
Change	-0.43%	+52.04%	+49.35%	+105.77%

Analyst Ratings

The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	14	14	14	13	14	14
Buy	5	6	6	6	6	6
Hold	5	6	6	6	7	7
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	24	26	26	25	27	27

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jessica Fye J.P. Morgan	J.P. Morgan	Buy Maintains $86	Buy	Maintains	$86	+42.71%	Sep 21, 2026
Debjit Chattopadhyay Guggenheim	Guggenheim	Buy Maintains $86	Buy	Maintains	$86	+42.71%	Sep 18, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Reiterates $124	Buy	Reiterates	$124	+105.77%	Sep 16, 2026
David Lebowitz BMO Capital	BMO Capital	Buy Reiterates $98 → $97	Buy	Reiterates	$98 → $97	+60.97%	Sep 15, 2026
Eric Joseph Citi	Citi	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Sep 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.91B

from 3.22B

21.30%

from 3.22B

Revenue Next Year

4.47B

from 3.91B

14.36%

from 3.91B

EPS This Year

4.94

from 3.15

56.86%

from 3.15

EPS Next Year

6.62

from 4.94

33.97%

from 4.94

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.85B	2.10B	2.42B	2.85B	3.22B	3.91B
Revenue Growth	-0.76%	13.53%	15.42%	17.97%	12.87%	21.30%
Operating Income	-74.32M	54.68M	185.77M	474.21M	650.73M	786.76M
Net Income	-64.08M	141.56M	167.65M	426.86M	348.90M	534.02M
EPS	-	-	-	-	3.15	4.94
EPS Growth	-	-	-	-	-10.51%	56.86%
Forward PE	85.79	39.00	38.98	17.86	12.37	12.20
Free Cash Flow	-	-	-	-	724.96M	754.50M
No. Analysts	-	-	-	-	-	24

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	3.9B
Avg	3.9B
Low	3.9B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	22.2%
Avg	21.3%
Low	20.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	5.07
Avg	4.94
Low	3.79

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	61.0%
Avg	56.9%
Low	20.3%